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ABSTRACT
Oxygen distribution is a major determinant of treatment success in radiotherapy, with well-oxygenated tumour regions
responding by up to a factor of three relative to anoxic volumes. Conversely, tumour hypoxia is associated with treatment
resistance and negative prognosis. Tumour oxygenation is highly heterogeneous and difficult to measure directly. The
recent advent of functional hypoxia imaging modalities such as fluorine-18 fluoromisonidazole positron emission
tomography have shown promise in non-invasively determining regions of low oxygen tension. This raises the prospect of
selectively increasing dose to hypoxic subvolumes, a concept known as dose painting. Yet while this is a promising
approach, oxygen-mediated radioresistance is inherently a multiscale problem, and there are still a number of substantial
challenges that must be overcome if hypoxia dose painting is to be successfully implemented. Current imaging modalities
are limited by the physics of such systems to have resolutions in the millimetre regime, whereas oxygen distribution varies
over a micron scale, and treatment delivery is typically modulated on a centimetre scale. In this review, we examine the
mechanistic basis and implications of the radiobiological oxygen effect, the factors influencing microscopic
heterogeneity in tumour oxygenation and the consequent challenges in the interpretation of clinical hypoxia imaging
(in particular fluorine-18 fluoromisonidazole positron emission tomography). We also discuss dose-painting approaches
and outline challenges that must be addressed to improve this treatment paradigm.
INTRODUCTION
In 1953, Gray et al1 had observed that the concentration of
oxygen in tissues markedly affects the response of animal
tumours to radiotherapy. This ﬁnding has been well rep-
licated up to the present day from a clinical perspective,2
with hypoxia associated with averse outcomes. In addition,
oxygen can greatly modify the response of a patient to
radiotherapy; for conventional X-ray therapy, regions of
a tumour with high oxygen concentration are up to three-
fold more amenable to treatment than anoxic regions.
Hypoxia in tumours is something of a vicious cycle prob-
lem, with low oxygen level both promoting aggressive
mutations and hampering treatment efﬁcacy.
Radiotherapy itself has continued to evolve steadily since its
introduction in the late 1800s.3 New treatment modalities
such as intensity-modulated radiotherapy (IMRT) have
emerged, which allow for the modulation of dose over
small volumes, of the order 1 cm3. Parallel to this, func-
tional imaging of tumour hypoxia is steadily becoming
a clinical reality, raising the tantalizing prospect of de-
livering increased dose to hypoxic regions with heightened
resistance. This concept is known as dose painting,4 where
increased dose might be given to hypoxic subvolumes.
Yet promising as dose painting is, there are still signiﬁcant
barriers to implementation of this promising modality. As
depicted in Figure 1, hypoxic treatment resistance is in-
herently a multiscale problem—the best functional imag-
ing of hypoxia is limited to the millimetre regime, whereas
oxygen diffusion varies over a micron scale. Similarly, the
impact of cellular oxygen consumption rate and vascular
distribution can create exceptionally heterogeneous oxygen
distributions. Even if hypoxia can be estimated, there is still
much more work required in order to derive robust
treatment plans for this eventuality.
If oxygen-mediated treatment resistance is to be overcome, these
aspects cannot be considered in isolation. In this review, we
consider the role of oxygen in radiobiological treatment re-
sistance, the current state of in vivo functional hypoxia imaging
and dose-painting methodology. In particular, we focus on the
role of oxygen in treatment resistance and enhancement and
functional imaging of in vivo hypoxia, as well as dose-painting
work to date. Finally, we look at potential future work in this
ﬁeld and outstanding challenges that need to be surmounted.
OXYGEN AND RADIOBIOLOGY
Hypoxia and phenotype selection
Since Gray’s initial observation in the 1950s, the deleterious
consequences of hypoxia have been observed across numerous
cancer types and sites.5–7 Under hypoxic conditions, tumour
cells can respond to hypoxia by activating oxygen-sensitive sig-
nalling pathways, including hypoxia-inducible-factor pathways8
and the unfolded protein response.9 Although the precise
mechanisms remain poorly understood, it is thought that these
signalling pathways alter gene expression in an attempt to pro-
mote survival under adverse conditions, and ultimately allow
cellular phenotypes to arise with evasive mutations, including
the ability to metastasize. To compound this, hypoxia also drives
angiogenesis, providing new routes for cancer cells to colonize,10
and affects cellular proliferation rates.11 The signals induced by
microenvironmental hypoxia ultimately allow for a cascade of
effects which eventually lead to the spread of tumour cells to
distant sites.12 Thus, the oxygen microenvironment has a strong
inﬂuence on how tumours will evolve and respond to treatment.
Oxygen enhancement ratio
The advantageous effect of oxygen on treatment response is
known as the oxygen enhancement ratio (OER), typically deﬁned
as the ratio of cell kill under well-oxygenated conditions relative to
that under anoxia. Under anoxia, the OER is unity and the ratio
increases with oxygen concentration. Although this can de deﬁned
in numerous ways, the most common formulation is given by
OER5
Cell kill in oxic conditions
Cell kill under anoxia
(1)
and typically has a maximum value of 2.7,3 suggesting that one
would have to deliver 2.7 times the dose to an anoxic region to
elicit the same level of cell kill. In reality, OER is not linear with
Figure 1. Oxygen-mediated treatment resistance as a multiscale problem.
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oxygen concentration, instead OER yields a curve where half-
maximum level manifests around 2.5–3mmHg. The effect
quickly saturates, obeying a roughly hyperbolic relationship with
oxygen partial pressure.3 Beyond partial pressures of 20mmHg,
no additional treatment beneﬁt is garnered by increasing oxygen
concentration. Furthermore, oxygen must be present at irradi-
ation or microseconds thereafter, as adding oxygen subsequent
to this does not improve therapy response.3,13
This OER curve is depicted in Figure 2 and has generally been
described empirically by approximation with hyperbolic func-
tions14 since the late 1950s. Although an equation of this form
describes the behaviour of the oxygen curve well, it does not posit
any mechanism of action for what has been observed. One likely
radiochemical rationale for this phenomenon is oxygen ﬁxation
hypothesis, which postulates that while most deoxyribonucleic
acid (DNA) can be repaired following radical damage, the pres-
ence of molecular oxygen with radical species produces a reactive
agent whose damage is more difﬁcult or impossible to reverse.
Under this schema, DNA damage from incoming high-energy
photons can be caused in a number of ways—direct damage
arises when the photon interacts with DNA, ionizing the mol-
ecule via Compton scattering. But more commonly, incoming
photons may interact with other matter, typically water. In these
ionization events, a high-energy electron is liberated. These
charged particles may impinge on other water molecules, cre-
ating highly reactive hydroxyl radicals (R_). This damage can be
readily chemically repaired, but if such radicals encounter an
oxygen molecule, they may combine to form a peroxyl radical
ðRO×2Þ. This damage is much more difﬁcult for the cell to re-
pair15 and is illustrated in Figure 3. Thus, the presence of mo-
lecular oxygen can “ﬁx” damage in an irreparable state.3,15
The mechanisms underpinning OER have been the subject of
more recent work,16 taking the ﬁrst principles rather than em-
pirical approach. This mechanistic treatment uses Poisson
statistics to estimate the likelihood of an interaction between
ionized DNA and an oxygen molecule, taking into account
a number of vital physical parameters, including the thermal
velocity and mean free path of oxygen molecules, the interaction
volume and the availability of oxygen per unit volume. Under this
schema, OER is a function of oxygen partial pressure p given by
OERðpÞ511fO
fD
ð12 e2wpÞ (2)
where p is the oxygen partial pressure in mmHg, fO=fD is the
ratio of cells killed by oxygen ﬁxation to those killed directly and
w is a parameter derived from the ﬁrst principles. This model
yields the familiar OER curve and ﬁts well to a range of
experimental data, including human cells, bacteria and yeast.
Despite the signiﬁcant biological differences between these
subjects, this analysis suggests consistent values of
fO=fD51:66 0:03 and w5 0.266 0.02mmHg
21 for conven-
tional photon treatments. This apparent biological invariance
strongly supports the contention that OER arises from radio-
chemistry, and this analysis provided further evidence that the
oxygen ﬁxation hypothesis is indeed the mechanism responsible
for the observed boosting effect of oxygen on radiotherapy.
Variation of oxygen enhancement ratio with linear
energy transfer
It is important to note that the maximum OER obtainable varies
with the energy of the radiation used. Experimental evidence
suggests that high-energy charged-particle radiation has
a markedly lower maximum obtainable OER, and some
Figure 2. A typical oxygen enhancement ratio (OER) curve,
saturating at p.20mmHg.
Figure 3. Oxygen fixation hypothesis: a high-energy electron
created by an X-ray photon (e2) impinges on a water molecule,
liberating a proton (p1) and creating a hydroxyl radical (OH_).
This reactive molecule then impacts on deoxyribonucleic acid
(DNA_), resulting in ionization damage, DNA. This can be readily
repaired to its original state (DNA-H), but in the presence of
molecular oxygen, a peroxy radical is formed (DNA-OO_), fixing
damage into a permanent irreparable state. Taken from Grimes
and Partridge with permission from Institute of Physics (IOP).16
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empirical functions exist to describe this reduction in OER with
increasing linear energy transfer (LET).17 The reason for this is
likely the relatively intuitive conclusion that with increasing LET,
direct damage becomes a more dominant process, and there is
correspondingly less excess damage due to oxygen ﬁxation. This
suggests that for increasing LET, fO=fD
approaches zero, with
direct damage dominating at high enough energy.
Factors influencing oxygen availability
Diffusion limited hypoxia
As oxygen diffuses from a source, it is consumed by cells around
it and, eventually, the oxygen concentration diminishes to zero.
In healthy tissue, this is well regulated and cells tend to have
adequate oxygen. In cancer, cell growth is abnormal and, as
a consequence, the oxygen supply is frequently inadequate,
leading to chronic hypoxia beyond the diffusion distance rn.
Experimentally, diffusion distance in tumour tissue has been
measured at between 100 and 200mm.18–23
The oxygen consumption rate (OCR) is of paramount impor-
tance in this process, and cells with a higher OCR have much
shorter diffusion lengths. The precise relationship between OCR
and diffusion limit depends on several factors, chief among
them being source geometry. Early mathematical frameworks
modelled vessels as cylindrical emitters,18,19,24 a formulation
known as the Krogh model. In limited circumstances, this can
work well, but many of its assumptions (such as strictly radial
diffusion) do not hold in complex tumour tissue.25
Part of the complication is that vascular environments in
tumours tend to be highly heterogeneous. One alluring experi-
mental model for investigating the relationship between OCR
and diffusion limited hypoxia is to instead use tumour sphe-
roids. These are three-dimensional aggregates of cancer cells,
with metabolic proﬁles more similar to in vivo tumours than
simple monolayers.26 If sufﬁciently small, spheroids grow ex-
ponentially initially, forming anoxic cores when they grow be-
yond the diffusion distance of oxygen.27 A typical spheroid is
illustrated in Figure 4. The spherical geometry lends itself to
analytical solutions,23 and it can be shown that the diffusion
limit of a spheroid rl is related to its OCR, a, by
rl5
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
6DpO
aV
r
(3)
where pO is the oxygen tension at the spheroid surface, D the diffusion
constant of the tissue and V53.03183107kgmmHgm23, a con-
stant arising from Henry’s law. When spheroids grow beyond
a radius of rl, they begin to develop anoxic cores. Analytical
relationships between the extent of the viable rim and anoxic
core, as well as the oxygen distribution have been previously
derived and validated. These extents are closely linked to cellular
OCR, which strongly inﬂuences the maximum dimensions that
a spheroid can obtain.
It is worth noting that tumours may have highly complex ge-
ometries and, in general, one cannot readily apply neat geom-
etries to the in vivo case, but these models give us some valuable
insight into how OCR shapes oxygen distribution throughout
the tumour environment. In these formulations, OCR is gen-
erally considered to be a constant, but it is also possible to
formulate oxygen consumption as a function of oxygen avail-
ability, typically obeying Michaelis–Menten-like kinetics. Even if
this is assumed, the resulting oxygen distributions show only
negligible difference from the constant consumption case.29
Vasculature and perfusion
Tumours typically display highly contorted and chaotic vascula-
ture, and these tortuous and irregular vessels lack the hierarchical
arrangement of healthy vessels.30–36 In addition to this, endo-
thelial cells in tumours tend to be abnormal32 and the secretion of
angiogenetic growth factors10 encourages the formulation of bi-
zarre vessel structures. In some instances, these microvessels are
only perfused by plasma or simply not perfused at all,2,36 therefore
despite the presence of a vessel, there may be no oxygen supplied
to the tumour region. In this environment, hypoxia can readily
become dominant even when there is apparent vascular supply. In
addition, perfusion may vary temporally, leading to regions of
acute hypoxia.37 Although the evidence is currently unclear, there
is also some suggestion that chronic hypoxia (limited by diffusion)
and transient hypoxia might have intrinsically different radio-
sensitivity proﬁles due perhaps to changes in the repair capacity of
cells chronically starved of essential nutrients, particularly
oxygen.38,39 This remains an open question, with further studies
needed to explore it more deeply.
SPATIAL MEASUREMENTS OF OXYGENATION
A number of methods have been developed to measure or infer
tissue oxygenation in vivo. Direct, invasive physical measure-
ments of oxygen concentration may be performed, e.g. using
polarographic electrodes40 or ﬂuorescence probes.41 However,
electrode responses are non-linear functions of the oxygen dis-
tribution within the sensitive volume (typically 100mm in di-
ameter), affecting their ability to detect extreme values of the
oxygen distribution.42,43 There are also considerable challenges
Figure 4. A DLD1 tumour spheroid, with external boundary
marked in red. The oxygen-limited anoxic core (blue outline) is
also shown. Green staining is the ki-67 proliferation marker and
red is the hypoxia marker EF5. Adapted from Grimes et al with
permission from Royal Society Interface.23
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in sampling a sufﬁciently large proportion of the tumour in
a spatially precise manner, as would be required to inform
a prescription for radiotherapy dose painting (although direct
spatially localized measurement of oxygenation has been dem-
onstrated in animals44).
Imaging constitutes an alternative framework in which measures
of oxygenation can be localized in three dimensions. Image
contrast relating directly to deoxyhaemoglobin concentration in
blood can be obtained using gradient-echo MRI;45 changes in
concentration can be induced by manipulating the inhaled gas
mixture (the blood-oxygen-level-dependent effect), enabling
qualitative assessment of intravascular PO2.
46–48 Although BOLD-
MRI methods provide information on oxygen sources within the
tumour, this is not sufﬁcient to reliably infer the oxygen con-
centration far from vessels (which also depends heavily on oxygen
consumption in particular). There has instead been considerable
focus on optimizing molecular hypoxia imaging, which measures
the concentration of a tracer molecule with oxygen-dependent
binding characteristic. In this paradigm, the signal has a biological
(as opposed to physical) interpretation and may arise anywhere in
tissue, assuming adequate tracer delivery.
Molecular hypoxia imaging
For biological hypoxia imaging to be effective, it is necessary to
detect very low concentrations of a molecule in tissue: positron
emission tomography (PET) and single-photon emission CT are
therefore used to image the distribution of a radiolabelled tracer,
having good speciﬁcity for detection due to low background
radioactivity in the human body. A wide range of tracers have
been proposed for clinical use in both modalities and have been
reviewed in detail elsewhere.49,50 The following discussion is
given in the context of a PET-based approach, which currently
offers better sensitivity,51 and often better spatial resolution in
the clinic than single-photon emission CT; however, many of the
points raised will be relevant to all molecular imaging.
In PET-based hypoxia imaging, image contrast arises from the
decay of a radiopharamaceutical (tracer), delivered to tissue via
the bloodstream. Existing research has predominantly focused on
two classes of hypoxia tracers. The ﬁrst of these is Cu-ATSM,
labelled with any of copper’s four long-lived positron-emitting
isotopes (60, 61, 62, 64); whilst the hypoxia-speciﬁc binding
characteristic and desirable uptake and washout properties have
been demonstrated both in vitro and in vivo, the detailed mech-
anism for retention has not yet been conclusively determined.52
The second class of tracers consists of ﬂuorine-18-labelled (18F)
nitroimidazoles and includes 18F-ﬂuoroazomycin-arabinoside
(18F-FAZA), 2-(2-Nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-[18F]
pentaﬂuoropropyl)-acetamide and 18F-ﬂuoromisonidazole
(18F-FMISO); these molecules bind to intracellular macro-
molecules as a result of two reduction processes, the ﬁrst of which
may be reversed in the presence of oxygen.53 We will discuss
nitroimidazoles, in particular the tracer 18F-FMISO, in more detail.
Static hypoxia positron emission
tomography imaging
Comparison of the length scales for oxygen gradients in tissue
(100mm) and the typical resolution of clinical PET (4mm)
highlights the potential for considerable heterogeneity of oxy-
genation within an image voxel. The image signal observed will
be an average measure of uptake in the entire voxel, but two
features of this process complicate the interpretation of hypoxia
PET: the non-linearity of the signal as a function of local PO2
and the variation of the signal as a function of cellularity.
Non-linearity In cellular studies, 18F-FMISO binding has been
found to display a sharp (but not instantaneous) increase as local
PO2 decreases. Half-maximal uptake values are reported in the
range 0.8–2.1mmHg,54–56 and the functional form of the re-
lationship is illustrated in Figure 5. It might therefore be suggested
that in the absence of other confounds, 18F-FMISO is indicative of
the cellular “hypoxic fraction”, where hypoxia is deﬁned as
#2mmHg. However, since the binding function is smooth, rather
than a simple threshold, and is also non-linear, a number of sce-
narios can lead to the same mean uptake value in a voxel. In
Figure 5, it can be seen that approximately the same signal would
be expected if 25% of a voxel was anoxic (but viable) and the
remainder well oxygenated, or if the voxel is 50%/50% split be-
tween 1.4mmHg and oxic, or if the whole voxel is at 4.2mmHg.
The radiobiological response would be likely to differ markedly
between these scenarios, as illustrated in Figure 2.
Cellularity Since the proposed mechanism for nitroimidazole
binding requires an active electron transport chain, no speciﬁc
binding would be expected in areas of necrosis or acellular
material.53,57,58 A reduction in misonidazole (MISO) uptake has
indeed been demonstrated in autoradiographic studies of sphe-
roids with necrotic cores,59–61 which develop due to anoxia, and
similar effects have been seen in necrotic regions of tumours in
rats using 18F-FMISO and 18F-ﬂuoroerythronitroimidazole auto-
radiography.62 In the case of glioblastoma, high 18F-FMISO up-
take has been shown as a predictor of micronecrosis in humans.63
At the clinical scale, subvoxel necrosis may reduce the maximum
signal achievable and cause it to occur at higher PO2. Simulation
studies illustrate the possible non-monotonic relationship be-
tween average voxel oxygenation and 18F-FMISO uptake56,64 in
the presence of subvoxel necrosis. Signiﬁcant proportions of
other biologically inert substances within a voxel such as air,
ﬂuid, mineral bone and connective material might be expected
to confound the hypoxia signal in a similar manner.
Both of these effects have been illustrated well in pre-clinical
comparisons of 18F-FAZA autoradiography and histology65,66
and also in computational simulations of FMISO in relation to
PO2 (Figure 6). Further biological complications may also exist;
for example, there are suggestions that the critical PO2 for
nitroimidazole binding varies somewhat with cell/tumour
type.67,68 Overall, static PET images are unlikely to provide
sufﬁcient information to quantify hypoxia in all scenarios.69
Additional information, e.g. in the form of tracer uptake dy-
namics, may resolve this situation.
Dynamic hypoxia positron emission
tomography imaging
The general effects of necrosis and the non-linear 18F-FMISO
binding relation are to introduce difﬁculties in distinguishing
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between voxels with good oxygenation and those with very poor
oxygenation. Perfusion would be expected to vary considerably
between these two scenarios and, since the tracer is administered
in the bloodstream, could be assessed by examining images ac-
quired at multiple time points after tracer administration (dy-
namic analysis). Furthermore, the slope of the time activity
curve may contain additional information regarding the fraction
of cells which bind tracer.
Simulations have shown that the ratio of the “late” 18F-FMISO
activity (mostly bound tracer, acquired 4h post injection) to “early”
activity (mostly perfusion, acquired during the ﬁrst 15min) result
in a much better correlation between image signal and average
tissue oxygenation.64 It is possible to identify characteristic time
activity curves for vasculature, hypoxia and necrosis,70 but (as with
a static analysis) all these features may be present in varying pro-
portions within a voxel. A wide range of kinetic modelling has been
Figure 5. Illustration of the non-linear binding relationship for fluoromisonidazole (FMISO) as function of PO2. The points show
experimental data from Rasey et al,54 and the line shows a hyperbolic functional form fitted to autoradiographic data from tumour
spheroids.56 (a) Logarithmic axis; (b) linear axis at low PO2.
Figure 6. A simulated mean oxygen and fluoromisonidazole (FMISO) uptake in 4-mm voxels (a–f) using a two-dimensional vessel
map with varying vascularity, calculated by the methods described in Warren and Partridge.56 Red points indicate simulated blood
vessel positions. Voxels (e) and (f) are predicted to show very similar binding, despite a large difference in PO2, due to the extent of
necrosis in voxel (e).
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carried out to estimate the relative contribution of some or all of
these features in a given region.71 Thorwarth et al72 developed
a detailed kinetic model that allows prediction of the signal that
originate in hypoxic cells for each voxel; pharmacokinetic modelling
has also been used to isolate maps of the hypoxia-speciﬁc binding
constant.73 A study comparing dynamic PET analysis to image-
guided PO2 measurements in animals has suggested that it enables
better discrimination of hypoxia than static PET analysis.74
DOSE PAINTING
The customization of radiotherapy prescriptions based on spa-
tial information from hypoxia imaging is known as dose
painting. In principle, this allows selective boosting dose to
radio-resistant regions. The ability to dose paint has been
demonstrated using a number of advanced radiotherapy tech-
niques, including ﬁxed ﬁeld IMRT, volumetric modulated arc
therapy, tomotherapy and proton therapy.75–78 These studies
indicate that complex non-uniform dose distributions can be
optimized and delivered with a range of techniques, with
broadly equivalent target coverage and dose conformity. How-
ever, proton therapy reduces integral dose to the entire patient.
Two separate paradigms have been proposed for translating
hypoxia images into dose prescriptions: dose painting by con-
tours (DPBC) and dose painting by numbers (DPBN).
Dose painting by contours
In DPBC, a threshold value for the boost volume is selected
based on, e.g. tumour-to-blood uptake ratio (T : B) $1.3 for
FMISO,79 standardized uptake value (SUV) $1.4 for Cu-
ATSM80 or SUV .50% mean muscle SUV for FAZA.81 Most
studies so far have taken this approach, as it is generally easier to
implement into conventional clinical workﬂow using commer-
cial treatment planning software. DPBC also (in general) pro-
duces less steep dose gradients or more contiguous/uniform
dose boost regions, which might make these dose distributions
slightly easier to create and deliver and more robust to spa-
tial errors.
Several authors have looked at the value of using multiple tracers
[18F-ﬂudeoxyglucose (18F-FDG), hypoxia or proliferation] to
identify boost regions within the target volume,80,82–86 although
the conclusion seems to be that there is little correlation between
the boost volumes delineated by each individual tracer, as they
are designed to identify different characteristics within the tu-
mour volume. Clausen et al87 compared delineating either the
“union” or the “intersection” of 18F-FDG and FMISO volumes,
ﬁnding that the “union” volumes are larger and, in some
patients, perhaps too large to be safely used for dose escalation.
Most of the FMISO dose-painting work in the current literature
concerns head and neck cancers, in particular planning studies
involving a small number of patients. Typical threshold values
for FMISO are T : B 1.3,79,88,89 and dose escalation is achievable
for the vast majority of cases. For example, Choi et al89 showed
the feasibility of dose escalation from 72Gy (2.4Gy per fraction)
to 78Gy (2.6 Gy per fraction) in 6 of 8 patients; Hendrickson
et al90 achieved a planned 10-Gy boost for every patient in
a cohort of 10, predicting a tumour control probability (TCP)
increase of 17%. Less satisfactory planning results were seen
when the segmented high-dose boost volume is too small to
achieve adequate dose coverage80 or when the tracer signal
occurs as multiple diffuse boost volumes.81 A clinical trial is
currently open-investigating FMISO dose painting in head and
neck cancer (NCT02352792).
Other tumour sites of interest studied using FMISO include the
rectum84 and pancreas.86 The rectum shows non-speciﬁc
FMISO uptake and diffusion through the bowel wall. The
reported seven patients with pancreatic cancer showed no cor-
relation between typical PET quantiﬁcation metrics and tumour
size, and hypoxia was only visible in two patients’ FMISO PET
scans. Early reports have also demonstrated the feasibility of
hypoxic dose painting using FMISO in the lung.91,92
Dose painting by numbers
DPBN is an alternative approach to dose painting, whereby
a prescription dose is individually calculated for every voxel of
a tumour, based on local biological information from multi-
modality imaging. Alber and Thorwarth82 described an elegant
(theoretical) framework, which could produce DPBN pre-
scriptions that are robust to imaging uncertainties. Sterpin
et al93 showed that such uncertainties may be addressed by
blurring and dilating the prescribed dose, accounting for ran-
dom and systematic errors, respectively, without the need for
explicit consideration by the treatment planning system. The
theoretical work by Thorwarth et al94 compared a uniform dose
boost and DPBN and found that DPBN results in a much higher
predicted improvement in TCP than a simple uniform boost.
DPBN schemes have been proposed whereby dose is escalated as
a linear function of image intensity, capped at various minimum
and maximum image intensities.94–97
Several groups have suggested “dose redistribution” rather than
dose escalation, since any improvement in TCP calculated for the
non-uniform dose plan will be “true” rather than just a result of
any increase in mean dose.75,76,80,87,98–100 Most of these authors
used commercial treatment planning systems. Malinen et al98
segmented the tumour in a canine subject into four compart-
ments according to the level of hypoxia, each with a calculated
TCP. The dose distribution was then designed to maintain con-
stant mean dose to the entire target volume but with each com-
partmental dose optimized to improve TCP. Systematic errors in
dose were less critical than random errors (where voxels were
randomly assigned to the “wrong” hypoxic compartment). Søvik
et al99 further showed that non-uniform dose was better than
uniform dose but that adaptive re-planning could further improve
TCP over the course of an 18-fraction treatment. Daily adaptive
re-planning was no better than re-planning twice weekly. Toma-
Dasu et al101 also examined a voxel-based dose prescription
method with dynamic and static hypoxia to achieve a TCP of 95%
(for which the dose prescription varied: 65–121Gy). Bowen
et al102 examined different methods of translating the hypoxia
histogram into a dose prescription based on either a polynomial
or sigmoidal function.
A variety of hypoxia imaging techniques have been explored as
a basis for dose painting, including dynamic contrast enhanced
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MRI (DCE-MR) and PET with the tracers Cu-ATSM, 18F-FAZA
and FMISO. Very useful information on treatment planning and
plan evaluation is also obtained from work using 18F-FDG or
18F-FLT (18F-3-deoxy-39-ﬂuorothymidine) for boost volume
delineation. The phase I safety trial for DPBN adaptive planning
for head and neck cancer describes a neat way of planning ra-
diotherapy treatments with complex prescriptions and multiple
time point planning scans.76 Each patient receives 32 fractions
delivered using 3 different treatment plans. Plan 1 (fractions
1–10) is DPBN using the ﬁrst functional imaging scan (in the
trial, this had two different dose levels), Plan 2 (fractions 11–21)
is DPBN using the second functional imaging scan and Plan 3
(fraction 22–32) is a uniform IMRT plan. The largest planning
studies76,96 (involving 21 and 20 patients, respectively) have used
18F-FDG as a tracer.
DISCUSSION AND CHALLENGES
Oxygen has a substantial impact on treatment response, and
hypoxia presents a serious impediment to therapy by increasing
radioresistance. In addition, a low oxygen microenvironment is
highly correlated with the development of metastatic pheno-
types and poor prognosis. Hypoxia is a selection pressure for
the evolution of phenotypes with the capacity to both endure
harsh environments and crucially to migrate beyond the
bounds of the tissue from whence they arose.10 These clones
have the capacity to proliferate and survive in hypoxic envi-
ronments,12 and while the exact interplay is still an area of
active study, the negative inﬂuence of hypoxia on prognosis has
long been appreciated.1 As the microscopic oxygen distribution
is highly heterogeneous, it is notoriously difﬁcult to characterize
in situ. Functional imaging using hypoxia tracers such as
FMISO PET may be suitable for determining regions of
substantial hypoxia. This information could then be used in
conjunction with OER data to prescribe a higher dose to low
oxygen regions and thereby help alleviate or overcome hypoxia-
mediated treatment resistance.
The experimental evidence to date suggests that in test–retest
repeatability, 70–80% of the hypoxic volume is stationary, al-
though a small transient component is also seen in some
patients.103–107 This makes boosting target volume deﬁnition
using baseline hypoxia imaging feasible in principle. Modelling
results also suggest that short-time-scale oxygenation variations
do not affect the formation of FMISO image contrast,56 al-
though much more investigation is required to answer these
questions rigorously. If multiple images are obtained, it might be
possible to gauge the patient-speciﬁc hypoxia stability, and if this
is taken during treatment, it may lead to the possibility of bi-
ologically adaptive treatment protocols, although much more
experimental data would be required to ascertain whether this
avenue has potential.
Hypoxic dose painting shows much promise and has been ex-
perimentally demonstrated in a number of studies, several of
which are discussed in this review. An example of the stages and
scales that must be considered to develop a dose-painting
strategy is illustrated in Figure 7, which describes an in silico
model of a lung tumour. This comprises a sphere positioned
inside the lung of an anthropomorphic phantom, with locally
varying oxygen distributions calculated at 100 mm resolution,
using previously published methods36 and a varying vascular
density function. Radial vascular density proﬁles are either
uniform, a step function (creating a ring around a centrally
avascular tumour), or ramped (increasing linearly with radius),
Figure 7. (a) A simulated microscopic oxygen distribution in a 5-cm diameter spherical tumour; inset: heterogeneity within the
region with size equivalent to a positron emission tomography voxel (map and histogram, dashed line represents mean). (b) A
simulated fluoromisonidazole (FMISO) distributions for a spherical tumour under different assumptions (see text: Discussion and
Conclusions, paragraph 3 for details). (c) Planned volumetric modulated arc therapy treatment. (d) An example line profile of
planned dose through the gross tumour volume, plotted against prescription (green: vascularized rim; red: boost to hypoxic core).
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as shown in Figure 7b. Local FMISO uptake at 4 hours post
injection was predicted using a model of tracer-binding kinet-
ics,56 which includes hypoxic necrosis. This was subsequently
convolved with a 4.5-mm full-width-at-half-maximum Gaussian
to simulate a measured PET image, which is shown in the right
half of each panel of Figure 7b. Representative prescription doses
were calculated for an image-derived hypoxic boost region, and
dose distributions were created using a commercial treatment
planning system (Eclipse™ v. 13), assuming realistic normal
tissue constraints. Although this process is possible in a com-
puter simulation where microscopic oxygen distribution is al-
ready “known”, the necessary information is not readily
obtainable in the clinic. Substantial biological and mathematical
research must therefore be carried out before a similar mecha-
nistic approach could be implemented in practice.
Although the ability to deliver selective dose boosts to discrete
spatial regions is within our means, a signiﬁcant number of
outstanding questions and unresolved challenges remain. Some
major issues are enumerated below:
(1) Imaging resolution: Functional hypoxia imaging holds much
allure, but it is important to note that the physics of PET
imaging systems limits their resolution to the millimetre
domain. As oxygen diffusion occurs over a micron scale, and
tumour oxygen distributions are highly heterogeneous in vivo,
the distribution of oxygenation within a measured voxel may
not be adequately represented by a single image value and
simple interpretation may be potentially misleading.
(2) Biological interpretation of images: The underlying assump-
tion of dose painting is that it is possible to inform radiation
prescriptions based on the information derived from
imaging, but there are several potential complications. As
illustrated in Figure 6a–f, factors such as necrosis might
confound the analysis of functional imaging data. There is
some evidence to suggest that different cell types have
varying FMISO binding characteristics, which itself would
potentially skew understanding.56 Certainly, OCR has been
demonstrated to differ signiﬁcantly between cell types,28
impacting oxygen distribution. As in situ tumours are highly
biologically heterogeneous, there may be different binding
characteristics and OCRs even within the same tumour.
(3) Mathematical modelling: Because of the physical limitations
of functional imaging and the inherent biological variation
even within tumours, more mathematical modelling is
urgently required to bridge the scale gap between that which
we can image and the most likely underlying biology. The
scale gap between what can be imaged and the oxygen
diffusion scale spans up to three orders of magnitude, and
there is no current method for accurately determining the
most likely underlying oxygen distribution in a voxel. To
address this, robust biologically informed mathematical
models are essential
(4) Dose delivery: Even if it were possible to produce an ideal
prescription dose distribution accounting for all the above
complications, constraints are imposed by existing dose
delivery techniques. Such limitations include the maximum
deliverable dose gradient and the accuracy of patient
positioning. Furthermore, without daily treatment adaptation,
changes in patient anatomy, such as tumour shrinkage and
weight loss, will also introduce uncertainties that must be
accounted for in the ﬁnal treatment plan.
In relation to imaging resolution, it is highly unlikely that this
can be signiﬁcantly improved for PET imaging due to funda-
mental physical constraints. Unless new modalities circumvent
this difﬁcultly, hypoxia image information will remain in-
trinsically limited and biological interpretation will be difﬁcult.
For example, the inset of Figure 7a depicts a histogram taken
from a known underlying microscopic oxygen distribution, with
a mean of p5 20 mmHg. However, this mean is potentially
misleading because a signiﬁcant portion of the volume lies below
this and therefore the single voxel-derived value may be skewed.
The question of how to translate from a functional hypoxia
image to a dose prescription remains largely unanswered. Fur-
ther biological research is needed to help inform this, and in
particular, new mathematical models are urgently required to
bridge the resolution gap. These models are vital if we are to
estimate the most likely underlying distributions and deliver
dose accordingly, but they remain challenging due to the com-
plex biology of the tumour microenvironment and the inverse
nature of the problem at hand.
Dose delivery issues may be overcome to some degree by recent
technological developments. Spot-scanned proton and heavy ion
therapies have the potential to deliver steeper dose gradients
than intensity-modulated photon approaches but introduce
additional considerations in the form of range uncertainties.
Adaptive treatments are already in routine clinical practice in
many centres but are rarely backed up by repeat biological im-
aging. 18F-FMISO PET, in particular, requires considerable
clinical resource and is burdensome for the patient, therefore is
unlikely to be suitable in this situation. Alternative approaches
may be necessary for daily biological adaptation, and the MR-
linear accelerator offers promise but will require its own detailed
characterization from physical and biological perspectives before
optimal protocols can be developed. In the studies cited in this
work, dose escalations of up to 15% were reported, but it is
likely that much higher increments would be required for
clinical signiﬁcance. Modern radiotherapy interventions may
make 100- to 120-Gy doses achievable in some circumstances,
whereas equivalent doses can deﬁnitely be achieved using ste-
reotactic treatment. However, there may be no need to go quite
this high; mechanistic modelling of re-oxygenation suggests that
more moderate boost doses may be sufﬁcient to obtain early re-
oxygenation and cure.108,109 The requisite level of dose boosting
to radioresistant hypoxic regions remains an open question.
This review has chieﬂy focused on presenting an overview of
tumour hypoxia and its detrimental consequences. Although the
concept of boosting dose to radioresistant regions has been
elucidated in some depth, it is important to note that this is
certainly not the only viable strategy to overcome hypoxia.
Chemical interventions might play a sizable role in tackling
hypoxia-induced treatment resistance. These include strategies
including breathing hyperoxic gas with compounds such as
carbogen, and hypoxic-speciﬁc cytotoxic agents. There is also
a growing role for hypoxic sensitizers such as nimorazole. Some
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of these agents derive their efﬁcacy from moderating oxygen
consumption rate and thus reducing hypoxia—gemcitabine, e.g.
is a well-known radiosensitizer and recent investigations have
suggested that it markedly decreases oxygen consumption in
treated cells28 thereby countering hypoxia. Although beyond the
scope of this review, it is important to note the promising po-
tential of chemical agents to address clinical hypoxia.
CONCLUSION
Tumour oxygenation is of paramount importance to both
treatment efﬁcacy and patient prognosis. Overcoming the neg-
ative effects of hypoxia is a complex and deeply interdisciplinary
problem and will take concerted research effort from interface
ﬁelds to resolve. In particular, the multiple spatial scales make it
a challenging problem, and these resolution gaps must be
bridged to maximize the effectiveness of dose painting. Never-
theless, pragmatic approaches have already been demonstrated
to be feasible and serve as a promising foundation on which
future research can be built.
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